Filtered By:
Cancer: Lung Cancer

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 1667 results found since Jan 2013.

MLL4 Regulates the Progression of Non-Small-Cell Lung Cancer by Regulating the PI3K/AKT/SOX2 Axis
CONCLUSION: Our findings identify an important role of MLL4 in lung carcinogenesis through transcriptional regulation of PIK3IP1, affecting the PI3K/AKT/SOX2 axis, and suggest that MLL4 could be a potential prognostic indicator and target for non-small cell lung cancer therapy.PMID:36701842 | DOI:10.4143/crt.2022.1042
Source: Cell Research - January 26, 2023 Category: Cytology Authors: Yang Yang Rongfang Qiu Qiaoyou Weng Ziwei Xu Jingjing Song Siyu Zhao Miaomiao Meng Dengke Zhang Chunli Kong Hailin Wang Min Xu Zhongwei Zhao Jiansong Ji Source Type: research

PHF5A Promotes Proliferation and Migration of Non-Small Cell Lung Cancer 
by Regulating of PI3K/AKT Pathway
This study aims to investigate the role of PHF5A in the proliferation and migration of NSCLC. Methods A549 and PC-9 PHF5A overexpression cell lines were constructed. PHF5A expression was decreased in H292 and H1299 cells by using siRNA. Flow cytometry was used to detect the cell cycle. MTT assay and clone formation assay were used to examine the proliferative ability of NSCLC, while migration assay and wound healing assay were performed to evaluate the ability of migration. Western blot analysis was used to measure the expressions of PI3K, p-AKT and the associated downstream factors. Results Up-regulation of PHF5A in A549 ...
Source: Chinese Journal of Lung Cancer - January 20, 2023 Category: Cancer & Oncology Source Type: research

Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47
KRAS is one of the most frequently activated oncogenes in human cancers. Although the role of KRAS mutation in tumorigenesis and tumor maintenance has been extensively studied, the relationship between KRAS and the tumor immune microenvironment is not fully understood. Here, we identified a role of KRAS in driving tumor evasion from innate immune surveillance. In samples of lung adenocarcinoma from patients and Kras-driven genetic mouse models of lung cancer, mutant KRAS activated the expression of cluster of differentiation 47 (CD47), an antiphagocytic signal in cancer cells, leading to decreased phagocytosis of cancer ce...
Source: Journal of Clinical Investigation - January 18, 2023 Category: Biomedical Science Authors: Huanhuan Hu, Rongjie Cheng, Yanbo Wang, Xiaojun Wang, Jianzhuang Wu, Yan Kong, Shoubin Zhan, Zhen Zhou, Hongyu Zhu, Ranran Yu, Gaoli Liang, Qingyan Wang, Xiaoju Zhu, Chen-Yu Zhang, Rong Yin, Chao Yan, Xi Chen Source Type: research

PDS5B inhibits the proliferation of A549 human lung cancer cells via downregulation of Wnt5a
Conclusion PDS5B inhibits lung cancer cell proliferation by down-regulating Wnt5a expression.PMID:36631010
Source: Cancer Control - January 11, 2023 Category: Cancer & Oncology Authors: Li Ma Tongtong Ma Wenjing Zhou Juan Li Yuyun Li Hui Xu Source Type: research

Ultrasound-mediated mesoporous silica nanoparticles loaded with PDLIM5 siRNA inhibit gefitinib resistance in NSCLC cells by attenuating EMT
Eur J Pharm Sci. 2023 Jan 5:106372. doi: 10.1016/j.ejps.2023.106372. Online ahead of print.ABSTRACTEpidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKIs) was one of the main drugs in the treatment of non-small cell lung cancer (NSCLC). Previous studies had demonstrated that PDZ and LIM Domain 5 (PDLIM5) played an important role in EGFR TKIs resistance. However, there was no feasible method to eliminate EGFR TKIs resistance by suppressing this gene. Here, we formulated a novel mesoporous silica-loaded PDLIM5 siRNA (Small interfering RNA) nanoplatforms. The results have shown that PDLIM5 siRNA could be effect...
Source: European Journal of Pharmaceutical Sciences - January 9, 2023 Category: Drugs & Pharmacology Authors: Hao Wu Wen-Hao Lv Yang-Yang Zhu Ying-Ying Jia Fang Nie Source Type: research

Cigarette smoke condensate induces centrosome clustering in normal lung epithelial cells
ConclusionsHere we report a novel role of cyclin D2 in the regulation of centrosome clustering, which could allow the identification of tumors sensitive to cyclin D2 inhibitors. Our data reveal a pathway that can be targeted to inhibit centrosome clustering by interfering with the expression of cyclin D2-associated genes.
Source: Cancer Medicine - January 9, 2023 Category: Cancer & Oncology Authors: Jose Thaiparambil, Chandra S. Amara, Subrata Sen, Nagireddy Putluri, Randa El ‐Zein Tags: RESEARCH ARTICLE Source Type: research

Downregulation of LRP/LR with siRNA inhibits several cancer hallmarks in lung cancer cells
FEBS Open Bio. 2022 Dec 29. doi: 10.1002/2211-5463.13544. Online ahead of print.ABSTRACTThe incidence and mortality rates of cancer are growing rapidly worldwide, with lung cancer being the most commonly occurring cancer in males. Human carcinomas circumvent the inhibitory pathways induced by DNA damage and senescence through the upregulation of telomerase activity. The 37 kDa/67 kDa laminin receptor (LRP/LR) is a cell surface receptor which plays a role in several cancer hallmarks, including metastasis, angiogenesis, cell viability maintenance, apoptotic evasion and mediating telomerase activity. We have previously shown ...
Source: Cancer Control - December 29, 2022 Category: Cancer & Oncology Authors: Monique J Bignoux Tyrone C Otgaar Martin Bernert Stefan F T Weiss Eloise Ferreira Source Type: research

Cancers, Vol. 15, Pages 124: EGFR-Tyrosine Kinase Inhibitors Induced Activation of the Autocrine CXCL10/CXCR3 Pathway through Crosstalk between the Tumor and the Microenvironment in EGFR-Mutant Lung Cancer
Jinhyoung Kang CXCL10 is a cytokine that is elevated during EGFR-TKI treatment in the tumor microenvironment of lung cancer. Here, we report an original study that the impact of the CXCL10/CXCR3 pathway on EGFR-TKI resistance in EGFR-mutant lung cancer through a cytokine array analysis during in vitro coculture with tumor cells and activated PBMCs treated with EGFR-TKI, as well as the serial analysis of CXCL10 in EGFR-mutant lung cancer transgenic mice during EGFR-TKI treatment. In EGFR-mutant tumor cells cocultured with activated PBMCs, EGFR-TKI treatment increased CXCL10 in the supernatant; this activated CXCR3 in t...
Source: Cancers - December 25, 2022 Category: Cancer & Oncology Authors: Sook-hee Hong Nahyeon Kang Okran Kim Soon Auck Hong Juyeon Park Joori Kim Myung-Ah Lee Jinhyoung Kang Tags: Article Source Type: research

Targeting regulation of VEGF by BPTF in non-small cell lung cancer and its potential clinical significance
ConclusionsBPTF positively regulates VEGF expression and its high expression predicts a better efficacy of bevacizumab treatment in NSCLC.
Source: European Journal of Medical Research - December 19, 2022 Category: Research Source Type: research

Extracellular vesicles (EVs) as diagnostic tools in the phenotypic determination of lung tumors
Immunotherapy has been one of the great advances in recent years for the treatment of advanced tumors. Our goal is to determine whether extracellular vesicles (EVs) are effective and appropriate tools for detecting and blocking immune checkpoints proteins (ICPs). We developed a method for tracing tumor content via an analysis of EVs surface makers in the bloodstream using the MAGPIX platform (Fig.1). As a proof of concept, we have developed the detection of 4 ICP-EV. We will use this technology to monitor the ICP-EV profile in patients undergoing immunotherapeutic treatment. Second, endothelial EVs will be used as drug car...
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Cambier, M., Muller, F., Henket, M., Remacle, C., Guiot, J., Struman, I. Tags: 11.01 - Lung cancer Source Type: research

Identify Bcl3 as a novel biomarker shared between severe asthma and lung cancer using next-generation RNA sequencing from archival FFPE tissue biopsies
Conclusion: Our findings indicate a Bcl3 a novel putative biomarker in pathogeneses of both severe asthma and lung cancer.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Salameh, L., Manasa Bhamidimarri, P., Elemam, N., Ali, N., Dairi, Y., Alsharhan, M., Tirmazy, S. H., Hamid, Q., Mahboub, B., Al Heialy, S., Hamoudi, R. Tags: 03.03 - Mechanisms of lung injury and repair Source Type: research

< em > In vitro < /em > synergistic activity of cisplatin and EGFR-targeted nanomedicine of anti-Bcl-xL siRNA in a non-small lung cancer cell line model
In this study, anti-Bcl-xL siRNA were formulated within an EGFR-targeted nanomedicine with scFv ligands (NM-scFv) and its activity was tested in the non-small cell lung cancer (NSCLC) cell line H460. The obtained NMs-scFv anti-Bcl-xL were suitable for intravenous injection with sizes around 100 nm, a high monodispersity level and good siRNA complexation capacity. The nanocomplex's functionalization with anti-EGFR scFv ligands was shown to allow an active gene delivery into H460 cells and led to approximately 63% of gene silencing at both mRNA and protein levels. The NM-scFv anti-Bcl-xL improved the apoptotic activity of ci...
Source: Cancer Control - November 24, 2022 Category: Cancer & Oncology Authors: Phuoc Vinh Nguyen Katel Herv é-Aubert Laurie Lajoie Yoann Misericordia Igor Chourpa St éphanie David Emilie Allard-Vannier Source Type: research

Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47
J Clin Invest. 2022 Nov 22:e153470. doi: 10.1172/JCI153470. Online ahead of print.ABSTRACTKRAS is one of the most frequently activated oncogenes in human cancers. While the role of KRAS mutation in tumorigenesis and tumor maintenance has been extensively studied, the relationship between KRAS and the tumor immune microenvironment is not fully understood. Herein, we identified a novel role of KRAS in driving tumor evasion from innate immune surveillance. In lung adenocarcinoma patient samples and Kras-driven genetic mouse models of lung cancer, mutant KRAS activated the expression of cluster of differentiation 47 (CD47), an...
Source: Clinical Lung Cancer - November 22, 2022 Category: Cancer & Oncology Authors: Huanhuan Hu Rongjie Cheng Yanbo Wang Xiaojun Wang Jianzhuang Wu Yan Kong Shoubin Zhan Zhen Zhou Hongyu Zhu Ranran Yu Gaoli Liang Qingyan Wang Xiaoju Zhu Chen-Yu Zhang Rong Yin Chao Yan Xi Chen Source Type: research